Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.

Surgery today - 1 Apr 2021

Kimura Ryuichiro, Ohtsuka Takao, Kubo Makoto, Kajihara Atsuko, Fujii Atsushi, Watanabe Yusuke, Mori Yasuhisa, Ikenaga Naoki, Nakata Kohei, Shindo Koji, Ohuchida Kenoki, Nakamura Masafumi

Abstract excerpt

PURPOSE: The aim of this study was to investigate the genetic mutation profiles of Japanese pancreatic ductal adenocarcinoma (PDAC) patients. METHODS: Next-generation sequencing was performed using FoundationOne® CDx on 17 PDAC patients who were treated by surgical resection at Kyushu University Hospital between February 2016 and January 2019. The tumor mutational burden and microsatellite instability status were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Neoadjuvant Therapy

Share to Pancreatectomy

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Smad4 Protein

Source

Identifiers

PMID: 32885350
DOI: 10.1007/s00595-020-02123-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.PMID 32885350Read ↗

[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)].Semantic proximity Read ↗

Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.Semantic proximity Read ↗

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.Semantic proximity Read ↗

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinomaSemantic proximity Read ↗

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.Semantic proximity Read ↗

The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.Semantic proximity Read ↗

Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.Semantic proximity Read ↗

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean PatientsSemantic proximity Read ↗

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.Semantic proximity Read ↗

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.